Alkem Laboratories announced the outcome of its Board meeting held on February 13, 2026. The Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025. Critically, the Board also declared an Interim Dividend of ₹43 per equity share (2150% on face value of ₹2) for FY 2025-2026. The record date for this dividend payment is set for February 20, 2026.
Board Meeting Outcome & Financial Approvals
Alkem Laboratories Ltd. convened a meeting of its Board of Directors on February 13, 2026, commencing at 11:00 a.m. and concluding at 01:45 p.m. The primary outcomes included the approval of the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2025.
Interim Dividend Declaration
In a significant move, the Board declared an Interim Dividend of ₹43/- (Rupees forty-three only) per equity share on the face value of ₹2/- per share for the financial year 2025-2026.
- The Record Date for determining the entitlement for this dividend is fixed as Friday, February 20, 2026.
- The Payment Date for the Interim Dividend will be on and from March 6, 2026.
Financial Highlights (Consolidated Results)
The consolidated results for the nine months ended December 31, 2025, showed a total comprehensive income attributable to owners of the company of ₹21,344.1 million, against ₹18,829.5 million in the previous corresponding nine-month period. Basic Earnings Per Share (EPS) for continuing operations stood at ₹172.74 for the nine months, compared to ₹155.54 previously.
For the quarter ended December 31, 2025, the consolidated Total Income reached ₹38,799.2 million, while Profit for the period attributable to owners was ₹6,360.2 million.
Standalone Financial Performance (Continuing Operations)
The standalone Statement of Financial Results reflected strong performance in continuing operations:
- Total Income for the nine months ended December 31, 2025, was ₹77,549.5 million.
- Profit after tax from continuing operations for the same period was ₹19,680.6 million.
- Standalone Basic EPS for continuing operations for the nine months was ₹164.60.
Exceptional Items Noted
Both the consolidated and standalone results included disclosure of exceptional items. For the consolidated entity, an incremental impact analysis related to new Labour Codes (effective November 2025) was classified as an exceptional item amounting to ₹527.9 million for the quarter and nine months ended December 31, 2025. Separately, the gain from the sale of the Indore manufacturing facility was reported as an exceptional item of ₹142.9 million in the nine-month results.
Auditor’s Review Conclusion
The Independent Auditor’s Review Report confirmed that, based on their review and consideration of reports from other auditors, nothing had come to their attention causing them to believe that the accompanying financial statements contained any material misstatement, adhering to the specified accounting standards and regulations.
Source: BSE
